<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2522">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596579</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-20635</org_study_id>
    <nct_id>NCT04596579</nct_id>
  </id_info>
  <brief_title>SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida</brief_title>
  <official_title>SARS-CoV-2 Immune Surveillance Among a Population Based Sample of Adults in Florida</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to understand the immune response (IgG) to SARS-CoV-2 to&#xD;
      fill critical knowledge gaps in the natural history of this virus and to inform the&#xD;
      development of future infection mitigation efforts. The study team aims to assess the&#xD;
      prevalence of circulating IgG antibodies to SARS-CoV-2 and the factors associated with&#xD;
      sero-prevalence. These data will be used to estimate the total population that has been&#xD;
      exposed to the virus (asymptomatic and symptomatic), the proportion of the population that&#xD;
      may be protected by natural immunity, and the proportion that is susceptible. Data obtained&#xD;
      from this research will be shared with the Florida Department of Health.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 9, 2020</start_date>
  <completion_date type="Anticipated">October 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 9, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants who test positive for SARS-CoV-2 antibodies at first visit</measure>
    <time_frame>At study start</time_frame>
    <description>All participants who respond to study invitation letter will be tested for SARS-CoV-2 antibodies after completing a web-based questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who test positive for SARS-CoV-2 antibodies at second visit</measure>
    <time_frame>At 4 weeks</time_frame>
    <description>Participants who tested positive for SARS-CoV-2 antibodies at first study visit will be tested for antibodies to SARS-CoV-2 again at 4 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who test positive for SARS-CoV-2 antibodies at third visit</measure>
    <time_frame>At 3 months</time_frame>
    <description>Participants who tested positive for SARS-CoV-2 antibodies at second study visit will be tested for antibodies to SARS-CoV-2 again at 3 months.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Participants age 18-34</arm_group_label>
    <description>Up to 300 participants age 18-34 who received an invitation by mail and are free of fever at time of interview.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants age 35-54</arm_group_label>
    <description>Up to 300 Participants age 35-54 who received an invitation by mail and are free of fever at time of interview.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants age 55-64</arm_group_label>
    <description>Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants 65 and over</arm_group_label>
    <description>Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SARS-CoV-2 Antibody Analysis</intervention_name>
    <description>10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.</description>
    <arm_group_label>Participants 65 and over</arm_group_label>
    <arm_group_label>Participants age 18-34</arm_group_label>
    <arm_group_label>Participants age 35-54</arm_group_label>
    <arm_group_label>Participants age 55-64</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Weck-cel Swab Collection</intervention_name>
    <description>A Weck-cel swab will be used to collect secretions from the mucosal epithelium</description>
    <arm_group_label>Participants 65 and over</arm_group_label>
    <arm_group_label>Participants age 18-34</arm_group_label>
    <arm_group_label>Participants age 35-54</arm_group_label>
    <arm_group_label>Participants age 55-64</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Web Based Questionnaire</intervention_name>
    <description>A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.</description>
    <arm_group_label>Participants 65 and over</arm_group_label>
    <arm_group_label>Participants age 18-34</arm_group_label>
    <arm_group_label>Participants age 35-54</arm_group_label>
    <arm_group_label>Participants age 55-64</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Community Sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Resident of Hillsborough County, Florida&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Currently not exhibiting symptoms of SARS-CoV-2 infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna R Giuliano, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinical-trials-research/clinical-trials</url>
    <description>Moffitt Cancer Center's Clinical Trials Website</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID -19</keyword>
  <keyword>SARC-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

